Testing in vivo

The main expertise of the EPO-GmbH consists in the preclinical testing of novel anticancer agents in animal experiments.

EPO uses for that purpose different mouse and rat strains maintained in modern and licensed animal facilities.


Animals and animal facilities

A broad panel of syngeneic (mouse and rat origin) and xenogeneic tumour models are available.


Tumour models:

syngeneic
xenogeneic

EPO has established a variety of unique patient-derived xenografts (breast, colon, leukaemia, lung ovarian and sarcoma).

The establishment of additional customer-submitted models can be performed by EPO.
 

Evaluation of:

Antitumour efficacy
Side effects
Immuno modulation
Pharmacokinetics and drug distribution
Pathohistology and clinical chemistry

 

Testing in vivo
   

 

Top


Copyright © 2007 of EPO GmbH - All rights reserved.     04. März 2008.